AKB-6899

Research use only, not for human use.

AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages.

AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages. AKB-6899 leads to stabilization of HIF-2α which induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth.(In Vitro):In murine bone marrow-derived macrophages, AKB-6899 (10 μM; 24 hours) increases the levels of HIF-2α protein, with no corresponding increase in HIF-1α. AKB-6899 shows no effect on HIF-1α accumulation or VEGF production.(In Vivo):In C57BL/6 mice injected with B16F10 murine melanoma cells, AKB-6899 (17.5 mg/kg; i.p.) significantly reduces tumor growth.

Western Blot Analysis Cell Line:Murine bone marrow-derived macrophages Concentration:10 μM Incubation Time:24 hours Result:Observed an increase in HIF-2α protein in cells.

Animal Model:6-8-week-old C57BL/6 mice injected with B16F10 murine melanoma cells Dosage:17.5 mg/kg Administration:i.p.; 3 times per week; for 16 days Result:Significantly reduced tumor growth.

AKB 6899 | AKB6899

Angiogenesis

VEGFR

Human H3 receptor

——

——

1007377-55-0

290.25

C14H11FN2O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (344.53 mM)

OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(F)c1

——

(-20℃)

With Ice Pack

≥ 2 years